Acute Myeloid Leukemia Cell Models for Research

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal expansion of myeloid progenitors. According to the World Health Organization (WHO), AML accounts for approximately 80% of adult acute leukemias, with an estimated global incidence of 4.3 per 100,000 individuals per year. In the United States, the National Cancer Institute (NCI) projects about 20,380 new cases and 11,310 deaths in 2024. The median age at diagnosis is 68 years, and the 5-year relative survival rate is approximately 31.7% for all stages combined (SEER data). Survival varies significantly by subtype and cytogenetic risk; favorable-risk AML (e.g., t(8;21), inv(16)) has a 5-year survival of ~65%, while adverse-risk (e.g., complex karyotype, TP53 mutations) has a survival of <10%. Key risk factors include prior chemotherapy, radiation exposure, and genetic predispositions such as Down syndrome and familial AML syndromes.

AML is an ideal model for studying leukemogenesis and drug response due to its well-characterized genetic landscape, availability of public datasets (TCGA, COSMIC), and the ease of culturing and genetically manipulating leukemic cell lines. The disease is driven by recurrent mutations in genes involved in signaling (FLT3, KIT), epigenetic regulation (DNMT3A, TET2, IDH1/2), and transcription factors (RUNX1, CEBPA). These mutations provide clear targets for gene editing to create isogenic models that mimic patient-specific alterations. Open questions include the role of clonal heterogeneity, minimal residual disease, and resistance mechanisms, which can be addressed using CRISPR-engineered cell lines.

AML pathogenesis involves cooperative mutations that confer proliferative advantage and block differentiation. Key pathways include:

• • Proliferation and Survival Signaling: Activation of receptor tyrosine kinases (e.g., FLT3, KIT) leads to downstream MAPK/ERK and PI3K/AKT/mTOR pathways, promoting cell growth and survival.
• • Epigenetic Dysregulation: Mutations in DNMT3A, TET2, IDH1/2 alter DNA methylation and histone modifications, leading to aberrant gene expression and blocked differentiation.
• • Apoptosis Evasion: TP53 mutations or overexpression of anti-apoptotic proteins (BCL2) prevent programmed cell death.
• • Transcription Factor Dysregulation: Mutations in RUNX1, CEBPA, and NPM1 disrupt normal myeloid differentiation programs.

These pathways often cooperate; for example, a class I mutation (e.g., FLT3-ITD) provides proliferative signals, while a class II mutation (e.g., NPM1c) impairs differentiation.

Data from TCGA and COSMIC.

AML cells exhibit aberrant activation of several signaling networks:

• • MAPK/ERK Pathway: Activated by FLT3-ITD and RAS mutations, leading to increased proliferation.
• • PI3K/AKT/mTOR Pathway: Promotes cell survival and metabolism; often activated by FLT3 and KIT mutations.
• • JAK/STAT Pathway: Constitutive activation via FLT3-ITD or JAK2 mutations, contributing to cytokine-independent growth.
• • Wnt/β-Catenin Pathway: Dysregulated in AML stem cells, promoting self-renewal.
• • NF-κB Pathway: Constitutively active in many AML cases, enhancing survival and drug resistance.

Key nodes include FLT3, KIT, RAS, PI3K, AKT, mTOR, STAT5, β-catenin, and NF-κB.

Common AML cell lines used in research include:

These lines are valuable for studying specific mutations. Organoid models, though less common for AML, are being developed to recapitulate the bone marrow microenvironment and support long-term culture of primary AML cells, enabling more physiologically relevant drug testing.

Animal models are essential for in vivo studies:

• • Patient-Derived Xenografts (PDX): Immunodeficient mice engrafted with primary AML cells; preserve patient-specific mutations and heterogeneity.
• • Genetically Engineered Mouse Models (GEMM): Knock-in or transgenic mice expressing AML-associated mutations (e.g., FLT3-ITD, NPM1c) to study leukemogenesis.
• • Induced Models: Use of Cre-lox or CRISPR to induce mutations in hematopoietic stem cells, allowing temporal control.

These models are used for drug efficacy testing and studying disease progression.

CRISPR-based gene editing enables the creation of isogenic cell lines that differ only in a specific genetic alteration, providing powerful tools for functional studies. Examples include:

• • Knockout Lines: Disruption of tumor suppressor genes (e.g., TP53, TET2) to study loss-of-function effects.
• • Knock-in Lines: Introduction of oncogenic point mutations (e.g., FLT3-ITD, NPM1c) to mimic patient mutations.
• • Reporter Lines: Tagging genes with fluorescent proteins to track protein expression or localization.

These models are commercially available from various sources and are sequence-verified, ensuring reliability. They are widely used for drug screening, target validation, and mechanistic studies.

Gene-edited cell lines are used to validate the function of genes implicated in AML. For example:

• • Knockout of DNMT3A in OCI-AML3 cells leads to altered methylation patterns and increased self-renewal, confirming its role as a tumor suppressor.
• • Knock-in of FLT3-ITD in MOLM-14 cells enhances proliferation and confers resistance to FLT3 inhibitors, validating the mutation as a drug target.
• • Knockout of TP53 in HL-60 cells results in increased genomic instability and resistance to apoptosis, highlighting its role in chemosensitivity.

Isogenic cell line pairs (wild-type vs. mutant) are ideal for high-throughput drug screening. For instance:

• • FLT3-ITD knock-in cells are used to screen for novel FLT3 inhibitors, with the wild-type counterpart serving as a control.
• • TP53 knockout cells are used to identify drugs that selectively kill p53-deficient cells, a common feature of relapsed AML.
• • Resistance modeling: Chronic exposure to a drug in gene-edited cells can select for resistant clones, revealing mechanisms of acquired resistance.

CRISPR screens using gene-edited cell lines can identify synthetic lethal interactions and biomarkers. For example:

• • Synthetic lethality: In AML cells with a specific mutation (e.g., IDH1), knocking out other genes can identify vulnerabilities that are selectively lethal to mutant cells, providing new therapeutic targets.
• • Biomarker identification: Gene-edited lines can be used to identify genes whose expression correlates with drug response, aiding in patient stratification.